08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

CBLB612: Phase II started

Cleveland began a placebo-controlled, Russian Phase II trial to evaluate a single dose of CBLB612 given before or after chemotherapy with doxorubicin and cyclophosphamide in at least 39 breast cancer patients. The study is supported...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Protectan CBLB612: Phase I data

A single-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single subcutaneous injections of 0.5-4 ug CBLB612 were generally well tolerated. The MTD was 4 ug CBLB612. CBLB612 also led to dose-dependent increases...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Cleveland BioLabs hematology news

The Ministry of Industry and Trade of the Russian Federation granted Cleveland a contract worth RUB139 million ($4.3 million) to fund development of Protectan CBLB612 over about three years. The synthetic lipopeptide derived from...
07:00 , Sep 29, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Toll-like receptor 2 (TLR2) In vitro and mouse studies identified TLR2 ligands that could help treat...
07:00 , May 6, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune; multiple sclerosis (MS) Toll-like receptor 2 (TLR2) A study in mice suggests that inhibiting TLR2...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Cleveland BioLabs, Zhejiang Hisun Pharmaceutical deal

Cleveland BioLabs granted Zhejiang Hisun an exclusive license to develop and commercialize Protectan CBLB612 in China for 20 years. The synthetic lipopeptide with a chemical structure derived from a component of the Mycoplasma cell...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Clinical News

Cleveland BioLabs preclinical data

In Rhesus macaques, a single dose of CBLB612 increased the number of progenitor stem cells in the bone marrow by 20-fold. The company said the increase was comparable to 4 daily injections of G-CSF. CBLB612...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Clinical News

Cleveland BioLabs preclinical data

In mice, a single dose of CBLB612 increased the number of progenitor stem cells in the bone marrow by 3-fold within 24 hours and by 10-fold in the peripheral blood within 4 days. CBLB612 is...